A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.
Kline
M W
MW
Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston 77030, USA.
Fletcher
C V
CV
Harris
A T
AT
Evans
K D
KD
Brundage
R C
RC
Remmel
R P
RP
Calles
N R
NR
Kirkpatrick
S B
SB
Simon
C
C
D000284:Administration, Oral; D000293:Adolescent; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D018791:CD4 Lymphocyte Count; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D016049:Didanosine / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008297:Male; D010865:Pilot Projects; D012367:RNA, Viral / Q000097:blood; D018119:Stavudine / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
D019380:Anti-HIV Agents; D012367:RNA, Viral; D019469:Indinavir; D018119:Stavudine; D016049:Didanosine